Demo Data from EDBT 2026 / reviewers in the wild / expert
Jody Groenendyk
dblp:155/1362
· DBLP profile ↗
1ranked-venue papers
0as first author
0since 2021 · last 2014
—ORCID · none
Domains — the database's venue-derived domains; a paper can count in several
Applied, interdisciplinary, general and emerging computing · 1
Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.
| Interdisciplinary, comprehensive, and emerging computing
1 paper |
Bioinformatics and computational biology · 100% |
Topics — the 3 heaviest of 3, each with the papers that count most for it
| Topic | Weight | Papers | Last | Evidence papers |
|---|---|---|---|---|
Bioinformatics and computational biology › drug discovery › target identification
drug target identification |
0.2 | 1 | 2014 | Human structural proteome-wide characterization of Cyclosporine A targets · Bioinform. 2014 |
Bioinformatics and computational biology › drug discovery › computational drug discovery
protein-ligand interaction prediction |
0.2 | 1 | 2014 | Human structural proteome-wide characterization of Cyclosporine A targets · Bioinform. 2014 |
Bioinformatics and computational biology › proteomics
structural proteomics |
0.1 | 1 | 2014 | Human structural proteome-wide characterization of Cyclosporine A targets · Bioinform. 2014 |
Methods — techniques the papers use, named apart from their topics
surface plasmon resonance · 0.2molecular dynamics · 0.2molecular docking · 0.2enzymatic assay · 0.2
| Year | Publication | Venue | Position |
|---|---|---|---|
| 2014 | Human structural proteome-wide characterization of Cyclosporine A targetsabstractMOTIVATION: Off-target interactions of a popular immunosuppressant Cyclosporine A (CSA) with several proteins besides its molecular target, cyclophilin A, are implicated in the activation of signaling pathways that lead to numerous side effects of this drug. RESULTS: Using structural human proteome and a novel algorithm for inverse ligand binding prediction, ILbind, we determined a comprehensive set of 100+ putative partners of CSA. We empirically show that predictive quality of ILbind is better compared with other available predictors for this compound. We linked the putative target proteins, which include many new partners of CSA, with cellular functions, canonical pathways and toxicities that are typical for patients who take this drug. We used complementary approaches (molecular docking, molecular dynamics, surface plasmon resonance binding analysis and enzymatic assays) to validate and characterize three novel CSA targets: calpain 2, caspase 3 and p38 MAP kinase 14. The three targets are involved in the apoptotic pathways, are interconnected and are implicated in nephrotoxicity. Gang Hu 0005, Jody Groenendyk, Khaled H. Barakat, Marcin J. Mizianty, Jishou Ruan, Marek Michalak, Lukasz A. Kurgan |
Bioinform. | 3 |